Abstract: Various designs of pluggable variable optical attenuator (VOA) are disclosed. A pluggable VOA has an optical fiber adaptor connected to an internal VOA via different fiber optical interface configurations. At least a pair of ports is provided to accept optical fibers or external optical fiber ferrules for optical pluggability. The VOA is controlled electronically or manually. To facilitate a control of the VOA via a hosting system, an electronic device and/or interface is provided. External commands take the control of the VOA and set an attenuation level within a specification when the pluggable variable optical attenuator device is connected to a hosting system.

Abstract: This description relates to the use of a polymer-conjugated interferon-beta as monotherapy or in combination with other cancer therapies.

Abstract: Attenuators used to regulate optical signals are disclosed. According to one aspect of the present invention, an assembly including an IR source and an IR sensor is provided to sense blockage of optical signals transmitted between two collimators via a fixed common light blocker that is driven by a stepper motor. The movement of the light blocker is sensed by a sensing assembly including an IR source and IR sensor. By detecting the photocurrent from the IR sensor and a feedback circuit, the attenuation of the optical signals can be well controlled.

Abstract: LIGHT-targeting molecules (e.g., LIGHT fusion molecules), anti-HER2 antibody molecules, compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.

Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Abstract: This invention provides novel replication-defective adenoviral vectors comprising an adenoviral genome in which the protein IX gene, preferably under the control of its own promoter, is in an inverted orientation relative to the direction of transcription of the native protein IX gene at a location where the protein IX gene normally resides, for production of replication-competent adenovirus (RCA) free, or substantially RCA-free, adenovirus preparations. Said vector preferably encodes a gene of interest. The invention relates to viral particles, host cells and compositions comprising said adenoviral vector. This invention further relates a method for propagating adenovirus preparations, free, or substantially free, of replication-competent adenovirus (RCA) particles, from host cells comprising vectors of this invention, for use to treat a subject suffering from a disease or disorder or to prevent a subject from getting a disease or disorder, such as cancer.

Abstract: Disclosed are replicatable viral DNA vectors encoding a site-specific DNA-altering enzyme and a DNA target recognized by the enzyme, the enzyme selectively converting, in a cell expressing the enzyme, the DNA vector to a rearranged form. The invention further relates to methods for assembling recombinant adenoviral DNAs. These methods include the steps of: (a) providing a first linearized DNA vector including a restriction site and a cos site and a second linearized DNA vector including the restriction site, an adenoviral nucleic acid molecule, and a cos site; and (b) ligating the first and second linearized DNA vectors, the ligation assembling a recombinant adenoviral DNA.

Abstract: Disclosed are replicatable viral DNA vectors encoding a site-specific DNA-altering enzyme and a DNA target recognized by the enzyme, the enzyme selectively converting, in a cell expressing the enzyme, the DNA vector to a rearranged form. The invention further relates to methods for assembling recombinant adenoviral DNAs. These methods include the steps of: (a) providing a first linearized DNA vector including a restriction site and a cos site and a second linearized DNA vector including the restriction site, an adenoviral nucleic acid molecule, and a cos site; and (b) ligating the first and second linearized DNA vectors, the ligation assembling a recombinant adenoviral DNA.

Abstract: Techniques for controlling and monitoring MEMS optical switches are disclosed. In one embodiment, an electronic feedback loop is employed to determine a control signal to a MEMS switch actuator in accordance with an instruction. The control signal is so determined in such a way that the switching statuses are maximally guaranteed. To generate an appropriate control signal, AC or DC impedances of the MEMS switch are detected and used to configure the control signal to drive the switch. When it is detected that the impedance changes do not meet respective thresholds, the control signal is adjusted. In the case that the stiction happens, the switch actuator is overcharged, discharged and repeatedly applied for a limited time to overcome the stiction.

Abstract: Disclosed are replicatable viral DNA vectors encoding a site-specific DNA-altering enzyme and a DNA target recognized by the enzyme, the enzyme selectively converting, in a cell expressing the enzyme, the DNA vector to a rearranged form. The invention further relates to methods for assembling recombinant adenoviral DNAs. These methods include the steps of: (a) providing a first linearized DNA vector including a restriction site and a cos site and a second linearized DNA vector including the restriction site, an adenoviral nucleic acid molecule, and a cos site; and (b) ligating the first and second linearized DNA vectors, the ligation assembling a recombinant adenoviral DNA.